A carregar...
Publicação
Vitrolife private equity investment committee paper - capital structure of the leveraged buyout
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 38.27 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Vitrolife is a leading provider of in-vitro fertilization products, offering medical Consumables,
Technological devices, and Genetic Testing services across the entire IVF journey. It is an
attractive target for a private equity fund, given its stable EBITDA margin, strong competitive
position in a high-growth market and its in-house R&D capabilities. Value creation is driven
through three strategies: Eastern Europe market penetration, AI-Partnership and forward
integration through the acquisition of Virtus Health. Based on an estimated exit multiple of
16.7x EBITDA, investors are expected to receive a 3.6x MM return over a six-year holding
period.
Descrição
Palavras-chave
Private equity Leveraged buyout Acquisition Vitrolife group Fertility services